PCSK9-Binding Polypeptides for LDL-Lowering Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel polypeptides that can specifically bind and inhibit PCSK9 to manage hypercholesterolemia and related cardiovascular diseases, as existing therapies have limitations.
Innovation Solution
Development of polypeptides with specific amino acid sequences that bind to PCSK9, including immunoglobulin VH and VL regions, with varying degrees of identity to reference sequences, to inhibit PCSK9 activity and modulate LDL levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to manage hypercholesterolemia, then treatment is provided, but therapeutic benefits are limited
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequences of immunoglobulin VH and VL regions to create polypeptides with optimized binding affinity to PCSK9. By varying specific amino acid positions and sequences, the invention generates polypeptides with enhanced therapeutic effectiveness compared to existing therapies, directly addressing the limitation of current treatment reliability.
2Reliability
If polypeptides with specific amino acid sequences are developed to bind PCSK9, then PCSK9 inhibition is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent applies local quality by specifying particular amino acid sequences in the immunoglobulin VH and VL regions while allowing flexibility in other areas. The defined sequence requirements (at least 55% identity to reference sequences with specific CDR regions) provide localized precision for PCSK9 binding while permitting broader manufacturing flexibility, balancing inhibition reliability with ease of production.
3Measurement precision
If polypeptides with high sequence identity to reference sequences are used, then PCSK9 binding specificity is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent applies parameter changes by establishing a minimum sequence identity threshold (at least 55%) rather than requiring exact matches. This parameter approach maintains sufficient binding specificity while providing manufacturing flexibility, allowing for acceptable variations in sequence accuracy without compromising therapeutic effectiveness.
Solution Approach 2:
The patent applies local quality by focusing sequence precision requirements on critical regions (immunoglobulin VH and VL with specific CDRs) while allowing greater flexibility in non-critical areas. This localized precision approach ensures adequate PCSK9 binding specificity without imposing stringent precision requirements across the entire polypeptide sequence, thereby reducing manufacturing complexity.
Data Source
AI summary
The disclosure provides, in various embodiments, polypeptides that specifically bind to proprotein convertase subtilisin/kexin type 9 (PCSK9) (e.g., human PCSK9). The disclosure also provides, in various embodiments, methods for treating diseases associated with increased low-density lipoprotein (LDL) levels in the blood (e.g., hypercholesterolemia and its related cardiovascular disease risk).